Our Objectives

  • Improve access to clinical trials for cancer patients
  • Expand the opportunity for patients to benefit from cutting edge treatments
  • Improve access to precision medicine
  • Improve the cancer patient experience and outcomes
  • Facilitate cancer research so that new drugs and therapies come online faster
Meet Our Board Members
  • “Essentially EVERY advance in cancer therapy has been dependent on the conduct of well-designed clinical trials. It is hard to overstate the importance of increased partnership between patients and their physicians which will allow increased participation in clinical trials, so that the pace of progress in reducing the burden of cancer can be accelerated.” Donald Trump, MD, FACP, FASCO
    CEO Emeritus, Inova Schar Cancer Institute
    Co-Director of the Breast Cancer Program
  • “It’s really important for individuals to keep an open mind about what clinical trials might be available and to talk about that with their physicians. Today’s treatment standards are based on yesterday’s clinical trials.” Vered Stearns, M.D.
    Co-Director of the Breast Cancer Program
  • “The importance of clinical trials can not be overstated. Researchers and clinicians should work together to bring clinical trials to the bedside so patients can avail and benefit from evolving technology and new drugs.” Jeanny B. Aragon-Ching, M.D.
    ACT Board Member, Co-Director of the Breast Cancer Program at Inova Schar Cancer Institute / Inova Fairfax Hospital
Jeanny B. Aragon-Ching, M.D.

Dr. Aragon-Ching is a specialty Oncology care physician board certified in medical oncology, hematology and internal medicine. She joins Inova Medical Group with over 15 years of clinical experience. She has a special interest in management of genitourinary (GU) cancers (prostate, bladder, kidney and testicular cancers).

Otis W. Brawley, MD, MACP, FASCO, FACE

Otis W. Brawley, M.D., is the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University. He is an authority on cancer screening and prevention and leads a broad interdisciplinary research effort focused on cancer health disparities at the Johns Hopkins School of Medicine, the Bloomberg School of Public Health and the Sidney Kimmel Comprehensive Cancer Center.

David Brown

David Brown brings over 40 years of management experience to his consulting, having held senior management positions in medical research, higher education, foundation management, investment management, and technology.

Pamela Brown

As founder and President of Brown Philanthropy Advisors, Pam has 30 years of experience in providing philanthropic advice, strategic planning, and management consulting to nonprofit and for-profit executives, board members, and donors seeking to maximize impact and effectiveness.

Robert Grossman

Robert L. Grossman is the Frederick H. Rawson Distinguished Service Professor in Medicine and Computer Science and the Jim and Karen Frank Director of the Center for Translational Data Science at the University of Chicago.

Adam R. Metwalli, MD

Adam R. Metwalli, MD, is a Professor in the Howard University College of Medicine and Chief of Urology in the Department of Surgery at Howard University Hospital. Dr. Metwalli is a urologic oncologist trained in robotic surgery and specializing in cancers of the kidney, prostate, bladder, penis and testis.

Donald L. Trump

Dr. Donald L. Trump, also known as Skip, FACP & M.D. serves as Chief Executive Officer and Executive Director of Inova Schar Cancer Institute at Inova Health Systems, Inc..